Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 107
Filter
1.
Mucosal Immunol ; 10(4): 1082-1096, 2017 07.
Article in English | MEDLINE | ID: mdl-28051083

ABSTRACT

Although previous studies have shown that CD4+ T cells expressing CCR6 and CD161 are depleted from blood during HIV infection, the mechanisms underlying their loss remain unclear. In this study, we investigated how the homeostasis of CCR6+ and CD161+ CD4+ T cells contributes to SIV disease progression and the mechanisms responsible for their loss from circulation. By comparing SIV infection in rhesus macaques (RMs) and natural host sooty mangabeys (SMs), we found that the loss of CCR6+ and CD161+ CD4+ T cells from circulation is a distinguishing feature of progressive SIV infection in RMs. Furthermore, while viral infection critically contributes to the loss of CD161+CCR6-CD4+ T cells, a redistribution of CCR6+CD161- and CCR6+CD161+CD4+ T cells from the blood to the rectal mucosa is a chief mechanism for their loss during SIV infection. Finally, we provide evidence that the accumulation of CCR6+CD4+ T cells in the mucosa is damaging to the host by demonstrating their reduction from this site following initiation of antiretroviral therapy in SIV-infected RMs and their lack of accumulation in SIV-infected SMs. These data emphasize the importance of maintaining CCR6+ and CD161+ CD4+ T-cell homeostasis, particularly in the mucosa, to prevent disease progression during pathogenic HIV/SIV infection.


Subject(s)
CD4-Positive T-Lymphocytes/immunology , HIV Infections/immunology , HIV-1/immunology , Intestinal Mucosa/immunology , Rectum/pathology , Simian Acquired Immunodeficiency Syndrome/immunology , Simian Immunodeficiency Virus/immunology , Animals , Cell Movement , Cercocebus atys , Disease Progression , Disease Reservoirs/virology , Female , Homeostasis , Humans , Intestinal Mucosa/virology , Macaca mulatta , NK Cell Lectin-Like Receptor Subfamily B/metabolism , Receptors, CCR6/metabolism
2.
Mucosal Immunol ; 10(4): 996-1007, 2017 07.
Article in English | MEDLINE | ID: mdl-27848950

ABSTRACT

Most HIV transmissions among men who have sex with men (MSM), the group that accounted for 67% of new US infections in 2014, occur via exposure to the rectal mucosa. However, it is unclear how the act of condomless receptive anal intercourse (CRAI) may alter the mucosal immune environment in HIV-negative MSM. Here, we performed a comprehensive characterization of the rectal mucosal immune environment for the phenotype and production of pro-inflammatory cytokines by CD4 and CD8 T cells, global transcriptomic analyses, and the composition of microbiota in HIV-negative MSM. Our results show that compared with men who had never engaged in anal intercourse, the rectal mucosa of MSM engaging in CRAI has a distinct phenotype characterized by higher levels of Th17 cells, greater CD8+ T cell proliferation and production of pro-inflammatory cytokines, molecular signatures associated with mucosal injury and repair likely mediated by innate immune cells, and a microbiota enriched for the Prevotellaceae family. These data provide a high-resolution model of the immunological, molecular, and microbiological perturbations induced by CRAI, will have direct utility in understanding rectal HIV transmission among MSM, and will enhance the design of future biomedical prevention interventions, including candidate HIV vaccines.


Subject(s)
Bacteroidaceae Infections/immunology , CD8-Positive T-Lymphocytes/immunology , HIV Infections/immunology , Microbiota/genetics , Mucous Membrane/immunology , Prevotella/genetics , Rectum/pathology , Th17 Cells/immunology , Adult , Cell Proliferation , Condoms/statistics & numerical data , Cytokines/metabolism , HIV Infections/prevention & control , HIV Infections/transmission , HIV Seronegativity , Homosexuality, Male , Humans , Inflammation Mediators/metabolism , Male , Sexual Behavior , Transcriptome , Young Adult
3.
Lupus ; 21(14): 1586-93, 2012 Dec.
Article in English | MEDLINE | ID: mdl-22936126

ABSTRACT

Minorities with systemic lupus erythematosus (SLE) are at high risk of poor disease outcomes and may face challenges in effectively self-managing multiple health problems. The Chronic Disease Self-Management Program (CDSMP) is an evidence-based intervention that improves the health of people with chronic illnesses. Although the CDSMP is offered by organizations throughout the United States and many countries around the world, it has not been tested among SLE patients. We pilot tested the benefits of the CDSMP in low-income African American patients with SLE. CDSMP workshops were delivered to 49 African American women with SLE who received medical care at a public lupus clinic in Atlanta, Georgia, US. We compared pre-post CDSMP changes (from baseline to 4 months after the start of the intervention) in health status, self-efficacy and self-management behaviors using self-reported measures. Additionally, we assessed health care utilization changes using electronic administrative records in the 6-month periods before and after the intervention. We observed significant improvements post-intervention in the SF-36 physical health component summary (mean change = 2.4, p = 0.032); self-efficacy (mean change = 0.5, p = 0.035); and several self-management behaviors: cognitive symptoms management (mean change = 0.3, p = 0.036); communication with physicians (mean change = 0.4, p = 0.01); and treatment adherence (mean change = 0.4, p = 0.01). The median number of outpatient visits decreased from 3 to 1 (p < .0001). The CDSMP is a promising intervention for low-income African Americans with SLE. It is an inexpensive program with growing availability around the world that should be further evaluated as a resource to improve patient-centered outcomes and decrease health service utilization among SLE patients.


Subject(s)
Health Status , Lupus Erythematosus, Systemic/therapy , Self Care , Self Efficacy , Adult , Black or African American , Ambulatory Care/statistics & numerical data , Chronic Disease , Evidence-Based Medicine , Female , Georgia , Humans , Medication Adherence/statistics & numerical data , Middle Aged , Office Visits/statistics & numerical data , Pilot Projects , Poverty
4.
Transplant Proc ; 43(10): 3892-8, 2011 Dec.
Article in English | MEDLINE | ID: mdl-22172867

ABSTRACT

Outcomes following lung transplant remain suboptimal. This is attributable to variable posttransplant recovery of lung function, and inconsistent degrees of lung function loss after peak function is reached. Granzyme B is elevated in the blood and bronchoalveolar lavage (BAL) in acute rejection. We hypothesized that persistent exposure to T cells high in granzyme B would negatively correlate with lung function. We investigated cumulative exposure measured as the area-under-the-curve (AUC) of CD8+ T cell granzyme Bhi cells in the first year posttransplant in both BAL and blood in 24 transplant recipients. We assessed the correlation between cumulative 1-year exposure and FEV1 slope. There was a negative correlation between 1-year exposure and FEV1 slope within the first year (r=-0.63; P=.001). This relationship persisted even when adjusted for transplant type, gender, age, rejection, and indication for transplantation. In contrast, no relationship was seen with the 1-year AUC and lung function after 1 year posttransplant. In contrast to the BAL granzyme Bhi levels, granzyme Bhi levels from the blood showed no relationship with lung function. These findings suggest that CD8+ T-cell-driven factors are responsible for early improvements in lung function after transplantation.


Subject(s)
CD8-Positive T-Lymphocytes/enzymology , Graft Rejection/enzymology , Granzymes/metabolism , Lung Transplantation/immunology , Lung/enzymology , Area Under Curve , Biomarkers/metabolism , Bronchoalveolar Lavage Fluid/immunology , Bronchoscopy , CD8-Positive T-Lymphocytes/immunology , Female , Forced Expiratory Volume , Georgia , Graft Rejection/immunology , Graft Rejection/physiopathology , Granzymes/blood , Humans , Least-Squares Analysis , Lung/immunology , Lung/physiopathology , Lung Transplantation/adverse effects , Male , Middle Aged , Spirometry , Time Factors , Treatment Outcome
5.
Transplant Proc ; 42(7): 2702-6, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20832573

ABSTRACT

PURPOSE: Gastric fundoplication (GF) for gastroesophageal reflux disease (GERD) may protect against the progression of chronic rejection in lung transplant (LT) recipients. However, the association of GERD with acute rejection episodes (ARE) is uncertain. This study sought to identify if ARE were linked to GERD in LT patients. METHODS: This single-center retrospective observational study, of patients transplanted from January 1, 2000, to January 31, 2009, correlated results of pH probe testing for GERD with ARE (≥International Society for Heart and Lung Transplantation A1 or B1). We compared the rates of ARE among patients with GERD (DeMeester Score > 14.7) versus without GERD as number of ARE per 1,000 patient-days after LT. Patients undergoing GF prior to LT were excluded. RESULTS: The analysis included 60 LT subjects and 9,249 patient-days: 33 with GERD versus 27 without GERD. We observed 51 ARE among 60 LT recipients. The rate of ARE was highest among patients with GERD: 8.49 versus 2.58, an incidence density ratio (IDR) of 3.29 (P = .00016). Upon multivariate negative binomial regression modeling, only GERD was associated with ARE (IDR 2.15; P = .009). Furthermore, GERD was associated with multiple ARE (36.4% vs 0%; P < .0001) and earlier onset compared with patients without GERD: ARE proportion at 2 months was 0.55 versus 0.26 P = .004). CONCLUSION: In LT recipients, GERD was associated with a higher rate, multiple events, and earlier onset of ARE. The efficacy of GF to reduce ARE among patients with GERD needs further evaluation.


Subject(s)
Gastroesophageal Reflux/etiology , Graft Rejection/epidemiology , Lung Transplantation/adverse effects , Acute Disease , Adult , Aged , Cytomegalovirus Infections/epidemiology , Female , Gastric Fundus/pathology , Gastroesophageal Reflux/epidemiology , Humans , Immunosuppressive Agents/therapeutic use , Lung Diseases/classification , Lung Diseases/surgery , Lung Transplantation/immunology , Male , Middle Aged , Retrospective Studies , Transplantation, Homologous
6.
Am J Transplant ; 10(4): 900-907, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20121754

ABSTRACT

Development of primary graft dysfunction (PGD) is associated with poor outcomes after transplantation. We hypothesized that Receptor for Advanced Glycation End-products (RAGE) levels in donor lungs is associated with the development of PGD. Furthermore, we hypothesized that RAGE levels would be increased with PGD in recipients after transplantation. We measured RAGE in bronchoalveolar lavage fluid (BALf) from 25 donors and 34 recipients. RAGE was also detected in biopsies (transbronchial biopsy) from recipients with and without PGD. RAGE levels were significantly higher in donor lungs that subsequently developed sustained PGD versus transplanted lungs that did not display PGD. Donor RAGE level was a predictor of recipient PGD (odds ratio = 1.768 per 0.25 ng/mL increase in donor RAGE level). In addition, RAGE levels remained high for 14 days in those recipients that developed severe graft dysfunction. Recipients may be at higher risk for developing PGD if they receive transplanted organs that have higher levels of soluble RAGE prior to explantation. Moreover, the clinical and pathologic abnormalities associated with PGD posttransplantation are associated with increased RAGE expression. These findings also raise the possibility that targeting the RAGE signaling pathway could be a novel strategy for treatment and/or prevention of PGD.


Subject(s)
Graft Rejection , Lung Transplantation , Receptors, Immunologic/metabolism , Tissue Donors , Biopsy , Humans , Receptor for Advanced Glycation End Products
7.
Aliment Pharmacol Ther ; 20(6): 601-6, 2004 Sep 15.
Article in English | MEDLINE | ID: mdl-15352907

ABSTRACT

BACKGROUND: Recent studies have suggested that mercaptopurine metabolism is influenced by drug formulation (mercaptopurine vs. azathioprine) and concomitant use of 5-aminosalicylic acid medications. AIM: To determine the influence of dose, formulation and 5-aminosalicylic acid use on mercaptopurine metabolism. METHODS: Metabolites from 131 inflammatory bowel disease patients were analysed. Logistic regression was used to analyse correlations between dose and metabolite levels. Multivariate analysis was used to determine the effects of drug formulation and 5-aminosalicylic acid use. RESULTS: A positive correlation was detected between dose and 6-tioguanine nucleotides levels for azathioprine/Imuran formulation (P = 0.005) but not for mercaptopurine formulation. Adjusted mean 6-tioguanine nucleotides levels were similar for both formulations. Adjusted mean 6-methylmercaptopurine levels were higher for mercaptopurine formulation than for azathioprine formulation (1950 vs. 1056, P = 0.04). 5-Aminosalicylic acid use: 6-tioguanine nucleotides levels did not differ based on concomitant 5-aminosalicylic acid use. However, 5-aminosalicylic acid use did result in higher adjusted mean 6-methylmercaptopurine levels: 2078 on 5-aminosalicylic acid vs. 991 off 5-aminosalicylic acid (P = 0.004). CONCLUSIONS: (i) Azathioprine may have metabolic benefits by achieving a correlation of dose with 6-tioguanine nucleotides levels and by leading to lower mean 6-methylmercaptopurine levels. (ii) 5-aminosalicylic acid use does not significantly impact 6-tioguanine levels and may lead to higher 6-methylmercaptopurine levels.


Subject(s)
Antimetabolites/chemistry , Azathioprine/chemistry , Inflammatory Bowel Diseases/drug therapy , Mercaptopurine/metabolism , Adolescent , Adult , Aged , Aminosalicylic Acids/therapeutic use , Antimetabolites/administration & dosage , Azathioprine/administration & dosage , Chemistry, Pharmaceutical , Dose-Response Relationship, Drug , Female , Humans , Inflammatory Bowel Diseases/metabolism , Male , Middle Aged , Regression Analysis
8.
Pediatr Dev Pathol ; 7(1): 61-70, 2004.
Article in English | MEDLINE | ID: mdl-15255036

ABSTRACT

Arteriopathy in human immunodeficiency virus (HIV)-infected patients is being increasingly recognized, especially in children. However, few studies have histologically evaluated the coronary arteries in HIV-infected children, and none have systematically assessed the aorta and pulmonary arteries. The coronary arteries, thoracic aorta, and the main and branch pulmonary arteries from the postmortem hearts of 14 HIV-infected children were systematically reviewed for vasculopathic lesions and compared with 14 age-matched controls. Findings from the HIV-infected children were compared with clinical, laboratory, and other postmortem findings. Coronary arteriopathy, seen in seven (50%) of the HIV-infected children, was primarily calcific, and it was associated with decreased CD3 and CD4 peripheral blood counts. Large vessel arteriopathy, seen in 9 (64%) of the 14 HIV-infected children, was primarily centered on the vasa vasorum and consisted mainly of medial hypertrophy and chronic inflammation. Large vessel lesions were associated with increased left ventricular mass z-scores (P = 0.02), and 78% of patients with large vessel arteriopathy had postmortem cardiomegaly. Coronary and large vessel arteriopathies are common in pediatric HIV-infection and have different clinicopathologic features suggesting different pathogenesis.


Subject(s)
Aortic Diseases/virology , Coronary Disease/virology , HIV Infections/complications , Pulmonary Artery , Vascular Diseases/virology , Aorta/pathology , Aortic Diseases/complications , Aortic Diseases/pathology , Cadaver , Child , Child, Preschool , Chronic Disease , Coronary Disease/complications , Coronary Disease/diagnostic imaging , Coronary Disease/pathology , Coronary Vessels/pathology , Echocardiography , Female , HIV Infections/immunology , Heart Diseases/complications , Humans , Immune Tolerance , Infant, Newborn , Male , Prospective Studies , Pulmonary Artery/pathology , Vascular Diseases/complications , Vascular Diseases/pathology
9.
Pediatrics ; 108(6): 1287-96, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11731650

ABSTRACT

OBJECTIVE: Many children with human immunodeficiency virus-1 (HIV-1) have chronic problems with growth and nutrition, yet limited information is available to identify infected children at high risk for growth abnormalities. Using data from the prospective, multicenter P2C2 HIV study, we evaluated the relationships between maternal and infant clinical and laboratory factors and impaired growth in this cohort. METHODS: Children of HIV-1-infected women were enrolled prenatally or within the first 28 days of life. Failure to thrive (FTT) was defined as an age- and sex-adjusted weight z score < or =-2.0 SD. Maternal baseline covariates included age, race, illicit drug use, zidovudine use, CD4+ T-cell count, and smoking. Infant baseline predictors included sex, race, CD4+ T-cell count, Centers for Disease Control stage, HIV-1 RNA, antiretroviral therapy, pneumonia, heart rate, cytomegalovirus, and Epstein-Barr virus infection status. RESULTS: The study cohort included 92 HIV-1-infected and 439 uninfected children. Infected children had a lower mean gestational age, but birth weights, lengths, and head circumferences in the 2 groups were similar. Mothers of growth-delayed infants were more likely to have smoked tobacco and used illicit drugs during pregnancy. In repeated-measures analyses of weight and length or height z scores, the means of the HIV-1-infected group were significantly lower at 6 months of age (P <.001) and remained lower throughout the first 5 years of life. In a multivariable Cox regression analysis, FTT was associated with a history of pneumonia (relative risk [RR] = 8.78; 95% confidence interval [CI]: 3.59-21.44), maternal use of cocaine, crack, or heroin during pregnancy (RR = 3.17; 95% CI: 1.51-6.66), infant CD4+ T-cell count z score (RR = 2.13 per 1 SD decrease; 95% CI: 1.25-3.57), and any antiretroviral therapy by 3 months of age (RR = 2.77; 95% CI: 1.16-6.65). After adjustment for pneumonia and antiretroviral therapy, HIV-1 RNA load remained associated with FTT in the subset of children whose serum was available for viral load analysis. CONCLUSIONS: Clinical and laboratory factors associated with FTT among HIV-1-infected children include history of pneumonia, maternal illicit drug use during pregnancy, lower infant CD4+ T-cell count, exposure to antiretroviral therapy by 3 months of age (non-protease inhibitor), and HIV-1 RNA viral load.


Subject(s)
Failure to Thrive/complications , Failure to Thrive/epidemiology , HIV Infections/complications , Adult , Child, Preschool , Female , HIV Infections/physiopathology , HIV Infections/transmission , HIV-1 , Humans , Infant , Infant, Newborn , Infectious Disease Transmission, Vertical , Male , Proportional Hazards Models , Prospective Studies , Risk Factors , Statistics, Nonparametric
10.
J Allergy Clin Immunol ; 108(2): 265-8, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11496244

ABSTRACT

Because HIV-1 infected infants with rapid progression (RP) of disease might benefit from early and intense antiretroviral therapy, the identification of predictive factors of RP becomes extremely important. Currently, the best predictive factors of RP in HIV-1 infected children are HIV-1 RNA levels and CD4-positive T-cell counts. A decrease in CD3-positive T-cell count has been identified as a predictive factor of AIDS development in HIV-1 infected adults. Our objective was to evaluate decreased number of CD3-positive T-cells as a predictive factor of RP in infants. Peripheral blood lymphocytes from HIV-1 infected infants (up to 6 months of age) were analyzed for an association of lymphocyte subsets with RP, which was defined as the occurrence of AIDS or death before 18 months of age. In infants with RP (n = 32), CD3-positive T-cell counts were 3093 cells/microL at <1 month of age, 3092 cells/microL at 1 to 3 months, and 2062 cells/microL at 3 to 6 months. Non-RP infants (n = 49) maintained their CD3-positive T-cells counts at approximately 4000 cells/microL for at least 6 months of life. CD3-positive and CD4-positive T-cell counts were significantly associated with RP. Our results suggest that a decreased CD3-positive T-cell count may be used to predict RP in HIV-1 infected infants (RR = 2.16, P =.001).


Subject(s)
CD3 Complex , HIV Infections/immunology , HIV-1 , T-Lymphocytes/cytology , Child, Preschool , Cohort Studies , Female , HIV Infections/mortality , Humans , Infant , Lymphocyte Count , Pregnancy , Prognosis , Prospective Studies , Risk Factors
11.
Circulation ; 104(3): 310-6, 2001 Jul 17.
Article in English | MEDLINE | ID: mdl-11457750

ABSTRACT

BACKGROUND: To assess the reliability of pediatric echocardiographic measurements, we compared local measurements with those made at a central facility. METHODS AND RESULTS: The comparison was based on the first echocardiographic recording obtained on 735 children of HIV-infected mothers at 10 clinical sites focusing on measurements of left ventricular (LV) dimension, wall thicknesses, and fractional shortening. The recordings were measured locally and then remeasured at a central facility. The highest agreement expressed as an intraclass correlation coefficient (ICC=0.97) was noted for LV dimension, with much lower agreement for posterior wall thickness (ICC=0.65), fractional shortening (ICC=0.64), and septal wall thickness (ICC=0.50). The mean dimension was 0.03 cm smaller in central measurements (95% prediction interval [PI], -0.32 to 0.25 cm) for which 95% PI reflects the magnitude of differences between local and central measurements. Mean posterior wall thickness was 0.02 cm larger in central measurements (95% PI, -0.18 to 0.22 cm). Mean fractional shortening was 1% smaller in central measurements. However, the 95% PI was -10% to 8%, indicating that a fractional shortening of 32% measured centrally could be anywhere between 22% and 40% when measured locally. Central measurements of mean septal thickness were approximately 0.1 cm thicker than local ones (95% PI, -0.18 to 0.34 cm). Centrally measured wall thickness was more closely related to mortality and possibly was more valid than local measurements. CONCLUSIONS: Although LV dimension was reliably measured, local measurements of LV wall thickness and fractional shortening differed from central measurements.


Subject(s)
Echocardiography/standards , HIV Infections/physiopathology , Heart Ventricles/diagnostic imaging , Ventricular Function, Left , Cardiac Volume , Child , Child, Preschool , Cross-Sectional Studies , Echocardiography/statistics & numerical data , Humans , Infant , Infant, Newborn , Longitudinal Studies , Observer Variation , Prospective Studies , Reproducibility of Results , Ventricular Function, Left/physiology
12.
Am J Gastroenterol ; 96(7): 2098-102, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11467638

ABSTRACT

OBJECTIVES: Inflammatory cytokines are released during acute pancreatitis. Interleukin 10 (IL-10) is a potent antiinflammatory cytokine with immunosuppressive and antiinflammatory activities. IL-10 has been shown to attenuate pancreatitis in an animal model. A double blind, placebo-controlled pilot study was conducted to evaluate the safety and efficacy of low dose IL-10 for the prevention of ERCP-induced pancreatitis. METHODS: Patients were randomized to receive a single i.v. dose of recombinant human IL-10 (8 microg/kg) or a placebo i.v. bolus injection 15 min before the procedure. Pancreatitis was defined as abdominal pain radiating to the back associated with elevated amylase or lipase two or more times the upper limit of normal requiring hospitalization for > or =2 days. Severity of pancreatitis was based on days of hospitalization. RESULTS: Two hundred patients were enrolled (101 IL-10, 99 placebo). No difference in age, gender, degree of pancreatic duct filling, therapeutic intervention, or complication was detected between the two groups. Eleven patients in the IL-10 group and nine patients in the placebo group had pancreatitis (p = 0.65). The median length of hospitalization was 4 days in the IL-10 group and 3 days in the placebo group (p = 0.75). CONCLUSIONS: IL-10 at the 8-microg/kg i.v. dose was not effective in reducing the incidence or severity of ERCP-induced pancreatitis. Further investigations are necessary to determine if manipulation of the cytokine pathway can prevent ERCP-induced pancreatitis.


Subject(s)
Cholangiopancreatography, Endoscopic Retrograde/adverse effects , Interleukin-10/therapeutic use , Pancreatitis/prevention & control , Double-Blind Method , Female , Humans , Interleukin-10/adverse effects , Male , Middle Aged , Pancreatitis/etiology , Pilot Projects , Treatment Outcome
13.
J Orthop Res ; 19(1): 117-25, 2001 Jan.
Article in English | MEDLINE | ID: mdl-11332607

ABSTRACT

Bone marrow harvested by aspiration contains connective tissue progenitor cells which can be induced to express a bone phenotype in vitro. The number of osteoblastic progenitors can be estimated by counting the colony-forming units which express alkaline phosphatase (CFU-APs). This study was undertaken to test the hypothesis that human aging is associated with a significant change in the number or prevalence of osteoblastic progenitors in the bone marrow. Four 2-ml bone marrow aspirates were harvested bilaterally from the anterior iliac crest of 57 patients, 31 men (age 15-83) and 26 women (age 13-79). A mean of 64 million nucleated cells was harvested per aspirate. The mean prevalence of CFU-APs was found to be 55 per million nucleated cells. These data revealed a significant age-related decline in the number of nucleated cells harvested per aspirate for both men and women (P = 0.002). The number of CFU-APs harvested per aspirate also decreased significantly with age for women (P = 0.02), but not for men (P = 0.3). These findings are relevant to the harvest of bone marrow derived connective tissue progenitors for bone grafting and other tissue engineering applications, and may also be relevant to the pathophysiology of age-related bone loss and post-menopausal osteoporosis.


Subject(s)
Aging/pathology , Bone Marrow Cells/physiology , Osteoblasts/physiology , Stem Cells/physiology , Adolescent , Adult , Aged , Aged, 80 and over , Cell Adhesion , Cell Count , Female , Humans , Male , Middle Aged , Sex Factors
14.
Am Heart J ; 141(4): 661-70, 2001 Apr.
Article in English | MEDLINE | ID: mdl-11275935

ABSTRACT

BACKGROUND: Vascular lesions have become more evident in human immunodeficiency virus type 1 (HIV)-infected patients as the result of earlier diagnosis, improved treatment, and longer survival. Aortic root dilation in HIV-infected children has not previously been described. This study was undertaken to determine the prevalence of aortic root dilation in HIV-infected children and to evaluate some of the potential pathogenic mechanisms. METHODS: Aortic root measurements were incorporated into the routine echocardiographic surveillance of 280 children of HIV-infected women: an older cohort of 86 HIV-infected children and a neonatal cohort of 50 HIV-infected and 144 HIV-uninfected children. RESULTS: By repeated-measures analyses, mean aortic root measurements were significantly increased in HIV-infected children versus HIV-uninfected children (P values of < or =.04 and < or =.005 at 2 and 5 years of age, respectively, for aortic annulus diameter, sinuses of Valsalva, and sinotubular junction). Heart rate, systolic blood pressure, stroke volume, hemoglobin, and hematocrit were not significantly associated with aortic root size. Left ventricular dilation, increased serum HIV RNA levels, and lower CD4 cell count measurements were associated with aortic root dilation at baseline. CONCLUSIONS: Mild and nonprogressive aortic root dilation was seen in children with vertically transmitted HIV infection from 2 to 9 years of age. Aortic root size was not significantly associated with markers for stress-modulated growth; however, aortic root dilation was associated with left ventricular dilation, increased viral load, and lower CD4 cell count in HIV-infected children. As prolonged survival of HIV-infected patients becomes more prevalent, some patients may require long-term follow-up of aortic root size.


Subject(s)
Aorta/pathology , HIV Infections/pathology , HIV-1 , Child , Child, Preschool , Dilatation, Pathologic , HIV-1/immunology , Humans , Prospective Studies , RNA, Viral/blood , Viral Load
15.
J Hepatol ; 34(1): 128-33, 2001 Jan.
Article in English | MEDLINE | ID: mdl-11211889

ABSTRACT

BACKGROUND/AIMS: Interferon-based regimens (alone or with ribavairin) are standard therapies for chronic hepatitis C. The aim of this study was to compare a 24-week regimen of interferon alpha-2b + ribavirin (IFN + RIBA) to interferon alpha-2b + amantadine (IFN + AMANT) in non-responders to previous interferon monotherapy. METHODS: In a multi-center, double-blind clinical trial, 118 patients (non-responders to previous interferon monotherapy) were equally randomized into the two arms: interferon alpha-2b (3 MU thrice weekly) and ribavirin (800 mg daily) vs. interferon alpha-2b (3 MU thrice weekly) and amantadine (200 mg daily). RESULTS: After 24 weeks of therapy, HCV RNA became undetectable in 34.8% (95% CI: 23.7-49.2) of IFN + RIBA and 19.6% (95% CI: 10.6-34.7) of IFN + AMANT (P = 0.10). This response was sustained in 3.9% (95% CI: 1.0-14.9) of IFN + RIBA and 0% of IFN + AMANT (P = 0.16). Ten patients from IFN + AMANT (17%) and 12 patients (20%) from IFN + RIBA were discontinued before completion of therapy. Of these, 7% in IFN + AMANT and 12% in IFN + RIBA were discontinued due to adverse effects. CONCLUSIONS: Re-treatment of interferon non-responders with a 24-week course of IFN + AMANT was not associated with any sustained viral eradication. Although IFN + RIBA in this group was associated with a reasonable end of treatment response, relapses were common and sustained responses were low.


Subject(s)
Amantadine/administration & dosage , Antiviral Agents/administration & dosage , Hepatitis C, Chronic/drug therapy , Interferon-alpha/therapeutic use , Ribavirin/administration & dosage , Adult , Aged , Double-Blind Method , Drug Therapy, Combination , Female , Hemoglobins/analysis , Hepatitis C, Chronic/psychology , Hepatitis C, Chronic/virology , Humans , Interferon alpha-2 , Interferon-alpha/administration & dosage , Male , Middle Aged , Quality of Life , Recombinant Proteins , Thyrotropin/blood
16.
Pediatrics ; 107(2): 328-38, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11158466

ABSTRACT

OBJECTIVES: To identify the causes of mortality in children with vertically transmitted human immunodeficiency virus (HIV) infection and to study age-related mortality trends. METHODS: In the multicenter P(2)C(2) HIV Study, 816 children born to HIV-infected mothers were followed for a median of 3.6 years. Two hundred five study participants with HIV infection were enrolled at a median age of 23 months; 611 were enrolled either prenatally or in the neonatal period before their HIV infection status was known. There were 121 deaths in study patients. The cause of death for all patients, its relationship to HIV infection, and pulmonary or cardiac involvement were determined. Age trends in disease-specific mortality were summarized for the HIV-related deaths. RESULTS: Ninety-three children died of HIV-related conditions. Infection was the most prevalent cause of death for children under 6 years of age with 32.3% caused by pulmonary infection and another 16.9% caused by nonpulmonary infection. The frequency of pulmonary disease as the underlying cause of death decreased significantly with increasing age: 5/9 (55.6%) by age 1, 1/12 (8.3%) after age 10 years. The frequency of chronic cardiac disease as the underlying cause increased with age-0% by age 1 year, 3/12 (25.0%) after age 10 years, as did the frequency of wasting syndrome with disseminated Mycobacterium avium complex-0% by age 1 year, 6/12 (50.0%) after age 10 years. CONCLUSIONS: Children with HIV who survive longer are less likely to die of pulmonary disease or infection and more likely to die of cardiac causes or with wasting syndrome.pediatric acquired immunodeficiency syndrome, mortality, human immunodeficiency virus.


Subject(s)
Cause of Death , HIV Infections/mortality , AIDS Dementia Complex/mortality , AIDS-Related Opportunistic Infections/mortality , Age Factors , Child , Child, Preschool , Female , Fetal Death , HIV Infections/transmission , HIV Wasting Syndrome/mortality , Heart Diseases/mortality , Humans , Infant , Infant, Newborn , Infectious Disease Transmission, Vertical , Longitudinal Studies , Lung Diseases/mortality , Male , Mortality/trends
17.
Hepatology ; 33(1): 196-200, 2001 Jan.
Article in English | MEDLINE | ID: mdl-11124836

ABSTRACT

Hepatitis C virus (HCV) is a major cause of chronic liver disease worldwide, affecting 175 million people globally. Over 80% of acutely infected patients go on to develop chronicity, but only 20% to 25% will develop end-stage liver disease and its complications. The sequelae of HCV-induced chronic liver disease accounts for 8,000 to 10,000 deaths annually in the United States and is currently the leading indication for liver transplantation. To date, there are no accurate noninvasive markers of disease activity and fibrosis. Liver biopsy is indicated to exclude other forms of liver pathologies and to establish the stage of liver disease. In this study, the role of liver biopsy in chronic hepatitis C was evaluated. Additionally, we calculated a discriminant score to predict cirrhosis in chronic hepatitis C infection. Our results showed that additional diagnoses or unsuspected diagnoses are less frequent than clinicians' suspected. We confirmed that the discriminant score for predicting cirrhosis is inferior to liver biopsy. In conclusion, the majority of patients with chronic hepatitis C will require a liver biopsy, which has an important implication on staging of the liver disease, prognosis, and possibly further management options.


Subject(s)
Hepatitis C, Chronic/complications , Hepatitis C, Chronic/pathology , Liver/pathology , Adult , Biopsy/standards , Diagnosis, Differential , Discriminant Analysis , Female , Forecasting , Hemochromatosis/diagnosis , Humans , Liver Cirrhosis/etiology , Liver Diseases/diagnosis , Male , Middle Aged
18.
J Clin Microbiol ; 38(11): 3942-5, 2000 Nov.
Article in English | MEDLINE | ID: mdl-11060049

ABSTRACT

A quality assurance program was established by the Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted Human Immunodeficiency Virus Type 1 Infection Study Group for monitoring cytomegalovirus (CMV) antibody and culture results obtained from nine different participating laboratories. Over a 3-year period, every 6 months, each laboratory was sent by the designated reference laboratory six coded samples: three urine samples for CMV detection and three serum samples for CMV immunoglobulin G (IgG) and IgM antibody determination. Overall, the participating laboratories exhibited the following composite performance statistics, relative to the reference laboratory (sensitivity and specificity, respectively): 100 and 97.4% for CMV cultures, 95.5 and 94.4% for CMV IgG antibody assays, and 92.6 and 90.2% for CMV IgM assays. The practice of having individual laboratories use different commercial methods and reagents for CMV detection and antibody determination was successfully monitored and provided useful information on the comparable performance of different assays.


Subject(s)
AIDS-Related Opportunistic Infections/diagnosis , Cytomegalovirus Infections/diagnosis , HIV Infections/complications , Infectious Disease Transmission, Vertical , Laboratories/standards , Antibodies, Viral/blood , Cardiovascular Diseases/complications , Child, Preschool , Cytomegalovirus/immunology , Cytomegalovirus/isolation & purification , Female , HIV Infections/transmission , Humans , Immunoenzyme Techniques/methods , Immunoenzyme Techniques/standards , Infant , Infant, Newborn , Pediatrics , Pregnancy , Quality Control , Respiratory Tract Diseases/complications , Sensitivity and Specificity , Urine/virology , Virus Cultivation/methods , Virus Cultivation/standards
19.
J Cell Biol ; 151(2): 381-8, 2000 Oct 16.
Article in English | MEDLINE | ID: mdl-11038184

ABSTRACT

Involucrin is synthesized in abundance during terminal differentiation of keratinocytes. Involucrin is a substrate for transglutaminase and one of the precursors of the cross-linked envelopes present in the corneocytes of the epidermis and other stratified squamous epithelia. These envelopes make an important contribution to the physical resistance of the epidermis. We have generated mice lacking involucrin from embryonic stem cells whose involucrin gene had been ablated by homologous recombination. These mice developed normally, possessed apparently normal epidermis and hair follicles, and made cornified envelopes that could not be distinguished from those of wild-type mice. No compensatory increase of mRNA for other envelope precursors was observed.


Subject(s)
Protein Precursors/genetics , Skin Physiological Phenomena/genetics , Animals , Epidermis , Gene Targeting , Genetic Vectors , Hair Follicle , Mice , Mice, Mutant Strains , Mutagenesis, Site-Directed , Reproduction
20.
J Allergy Clin Immunol ; 106(3): 559-66, 2000 Sep.
Article in English | MEDLINE | ID: mdl-10984378

ABSTRACT

BACKGROUND: Peripheral blood CD4(+) and CD8(+) T cells, CD19(+)/20(+) B cells, and serum Igs are known to be altered by the progression of pediatric HIV-1 infection, but their evaluation as predictors of survival needs further definition. OBJECTIVE: To determine the natural history of these immune factors and their importance in predicting survival, we studied 298 HIV-1 vertically infected (HIV-1(+)) children over a 5-year period. METHODS: These immune factors and serum HIV-1 RNA levels were measured in two groups: (1) a birth cohort of children enrolled up to age 28 days postnatally, including 93 HIV-1(+) and 463 HIV-1 uninfected infants (HIV-1(-)), and (2) an older cohort of 205 HIV-1(+) children enrolled after the age of 28 days, who were classified as survivors or nonsurvivors. RESULTS: In the birth cohort HIV-1(+) children had significantly lower CD4(+) T-cell counts, higher CD8(+) T-cell counts, and lower CD19(+)/20(+) B-cell counts and higher IgG, IgA, and IgM levels than HIV-1(-) children. In the older cohort survivors had significantly higher CD4(+) and CD8(+) T-cell and CD19(+)/CD20(+) B-cell counts and higher IgG, lower IgA, and lower IgM levels than did nonsurvivors. In univariable analysis factors affecting survival in the older cohort were baseline CD4(+) and CD8(+) T-cell and CD19(+)/20(+) B-cell counts and IgG and HIV-1 RNA levels (all P <.05). In multivariable analysis high baseline CD4(+) T-cell count and low baseline HIV-1 RNA load remained important. CONCLUSION: The longitudinal mean profiles of CD4 and CD8 T-cell and CD19/20 B-cell counts and serum IgG levels helped to describe the natural progression of HIV-1 disease in children. However, only baseline CD4 T-cell count independently predicted survival.


Subject(s)
Antigens, CD19/blood , Antigens, CD20/blood , CD4-Positive T-Lymphocytes/cytology , CD8-Positive T-Lymphocytes/cytology , HIV Seropositivity/pathology , Immunoglobulins/blood , B-Lymphocyte Subsets/pathology , Child , Child, Preschool , Cohort Studies , Female , HIV Seropositivity/mortality , HIV-1/genetics , Humans , Infant , Infant, Newborn , Lymphocyte Subsets/immunology , Male , Prospective Studies , RNA, Viral , Survival Rate , Viral Load
SELECTION OF CITATIONS
SEARCH DETAIL
...